FDA APPROVES PEMBROLIZUMAB FOR ADVANCED OR METASTATIC ESOPHAGEAL/GASTROESOPHAGEAL JUNCTION CANCER
The United States Food and Drug Administration (FDA) has granted approval for Merck’s anti-programmed death ligand-1 (PD-L1) therapy pembrolizumab (Keytruda) to be used in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinoma. The approval applies specially to treatment of tumors with an epicenter 1 […]
